Tarlatamab Biosimilar Bispecific scFv Antibody (DLL3 × CD3) for Research

Cat No.: GMP-Bios-ab-552

Pre-Made Tarlatamab biosimilar, Bispecific scFv, Anti-DLL3;CD3E Antibody: Anti-SCDO1;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tarlatamab is a half-life extended delta-like protein 3 (DLL3)/anti-CD3 bispecific T-cell engager (HLE BiTE) antibody construct, being developed by Amgen for the treatment of small cell lung cancer, neuroendocrine prostate cancer and metastatic melanoma.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-552-1mg 1mg
GMP-Bios-ab-552-10mg 10mg
GMP-Bios-ab-552-100mg 100mg
GMP-Bios-ab-552-xmg >100mg



Product Details

Products Name (INN Index) Pre-Made Tarlatamab biosimilar, Bispecific scFv, Anti-DLL3;CD3E Antibody: Anti-SCDO1;T3E/TCRE/IMD18 therapeutic antibody
INN Name Tarlatamab
TargetDLL3;CD3E
FormatBispecific scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommended2021
CompaniesAmgen
Conditions Approvedna
Conditions ActiveSmall cell lung cancer
Conditions Discontinuedna
Development TechBiTE Technology



About target - DLL3

1. Protein Delta-like protein 3

2. Gene DLL3

3. Organism Homo sapiens (Human)

Function
Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity).